文献速递头颈与中枢神经肿瘤

局部晚期喉癌和下咽癌诱导化疗后放疗喉保留:基于临床评估、CT容积测量和18F-FDG-PET/CT的评分在一個周期诱导化疗后预测结局

Induction chemotherapy followed by radiotherapy for larynx preservation in advanced laryngeal and hypopharyngeal cancer: Outcome prediction after one cycle induction chemotherapy by a score based on clinical evaluation, computed tomography-based volumetry and 18F-FDG-PET/CT.
PubMed 文献 · Eur J Cancer · 2016-12-26

研究纳入52例接受TPF±西妥昔单抗诱导化疗的局部晚期喉癌或下咽癌患者,用内镜肿瘤表面缩小率<30%筛选非应答者行全喉切除术,应答者接受诱导化疗+放疗。基于CT容积测量和18F-FDG-PET/CT构建的LFS评分≤16分预测应答者喉无进展生存、肿瘤特异性生存和总生存改善(p<0.05),评分>16分定义不适合喉保留方案的患者。

要点

  • IC-1后39/52例(75%)为早期应答者,早期应答预测IC+RT的完全缓解(p=8.48×10-9)。
  • LFS评分综合>2个N+、残留原发肿瘤体积>20%、残留总肿瘤体积>5.6 mL和resSUVmax/resSUVmean>1.51,按风险比加权(12、6、5、4)。
  • LFS评分≤16分预测应答者喉无进展生存、总生存和肿瘤特异性生存改善(p<0.05)。

核心结论

  • LFS评分≤16分可在IC-1应答者中识别从非手术喉保留获得最大长期LFS获益的患者。
  • LFS评分>16分定义采用TPF/TP IC+RT方案不适合喉保留的患者。

研究设计与样本

  • 52例局部晚期喉癌或下咽癌患者接受一个周期TPF±西妥昔单抗诱导化疗。
  • IC-1后内镜肿瘤表面缩小率<30%的非应答者行全喉切除术,应答者接受诱导化疗+放疗。
  • 用CT容积测量评估原发肿瘤、颈部淋巴结及其总和体积,18F-FDG-PET/CT测量SUVmax和SUVmean。

主要发现

  • IC-1后39/52例(75%)为早期应答者,早期应答预测IC+RT的完全缓解(p=8.48×10-9)。
  • 早期行全喉切除术的非应答者和内镜肿瘤表面缩小率>70%的应答者总生存最佳。
  • 应答者中LFS的显著独立预测因素包括CT分期可疑阳性颈部淋巴结数(N+)、残留原发肿瘤体积、残留总肿瘤体积及resSUVmax/resSUVmean比值。
  • LFS评分≤16分预测喉无进展生存、总生存和肿瘤特异性生存改善(p<0.05)。

关键数值与推荐

  • LFS评分组成:>2个N+(权重12)、残留原发肿瘤体积>20%(权重6)、残留总肿瘤体积>5.6 mL(权重5)、resSUVmax/resSUVmean>1.51(权重4)。
  • LFS评分≤16分预测喉无进展生存、总生存和肿瘤特异性生存改善(p<0.05)。
  • 早期应答预测IC+RT完全缓解(p=8.48×10-9)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Long-term laryngectomy-free (LFS), tumour-specific (TSS) and overall survival (OS) is achieved by non-surgical larynx preservation (LP) only in a proportion of patients with locally advanced laryngeal or hypopharyngeal cancer. A score facilitating decision-making after 1 cycle induction chemotherapy (IC-1) may improve LFS and TSS. METHODS: Early response to IC-1 with TPF ± cetuximab was assessed in 52 patients using endoscopic tumour staging for selecting total laryngectomy for non-responders with endoscopic tumour surface shrinkage <30% versus induction chemotherapy plus radiotherapy (IC + RT) for responders. Computed tomography (CT)-based volumetry was used to assess volumes of primary tumour, neck nodes and their sum; maximum and mean standardised uptake value (SUVmax, SUVmean) were measured by 18F-FDG-PET/CT. Baseline and residual values after IC-1 were calculated and correlated with LFS, TSS and OS. RESULTS: After IC-1, 39/52 patients (75%) were early responders. Early response predicted complete response to IC + RT (p = 8.48 × 10-9). Early laryngectomised non-responders and responders with endoscopic tumour surface shrinkage > 70% had best OS. Significant independent predictors for LFS in responders are number of CT-staged suspect positive neck nodes (N+), residual primary tumour volume, residual total tumour volume and the ratio of residual SUVmax and SUVmean (resSUVmax/resSUVmean). Our LFS-score combines >2N+, residual primary tumour volume > 20%, residual total tumour volume > 5.6 mL and resSUVmax/resSUVmean > 1.51 weighted by their hazard ratio (12, 6, 5 and 4); LFS-score ≤ 16 predicts increased LFS, OS and TSS (p < 0.05). CONCLUSION: LFS-score ≤ 16 identifies in responders to IC-1 the patients with maximum benefit of non-surgical LP achieving long-term LFS. Even more importantly, a LFS-score > 16 defines patients unsuitable for LP applying the TPF/TP IC + RT protocol.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Wichmann G, Krüger A, Boehm A, et al. Induction chemotherapy followed by radiotherapy for larynx preservation in advanced laryngeal and hypopharyngeal cancer: Outcome prediction after one cycle induction chemotherapy by a score based on clinical evaluation, computed tomography-based volumetry and 18F-FDG-PET/CT. Eur J Cancer. 2016. PMID: 28033526. doi:10.1016/j.ejca.2016.11.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。